Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James Larkin

Showing results (171-180 of 418) with videos related to

Pageof 42
Sort By:
Journal of Nephrology|November 1, 2025
Green haemodialysis: comparison of dialysis bags versus fresenius granumix at the AOU Policlinico di Modena, ItalyJames Larkin, Gaetano Alfano, Giulia Ligabue, et al.
Journal for Immunotherapy of Cancer|June 14, 2020
Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategyJohn Haanen, Marc Ernstoff, Yinghong Wang, et al.
American Journal of Clinical Oncology|January 30, 2013
Axitinib for the treatment of metastatic renal cell carcinoma: recommendations for therapy management to optimize outcomesJames Larkin, Mayer Fishman, Laura Wood, et al.
Expert Opinion on Pharmacotherapy|December 22, 2012
Second-line treatments for the management of advanced renal cell carcinoma: systematic review and meta-analysisJames Larkin, Abby Paine, Indra Tumur, et al.
Cancer Chemotherapy and Pharmacology|November 6, 2013
A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC)Ana M Molina, Thomas E Hutson, James Larkin, et al.
Cancer Cell|April 16, 2015
Intravital imaging reveals how BRAF inhibition generates drug-tolerant microenvironments with high integrin β1/FAK signalingEishu Hirata, Maria Romina Girotti, Amaya Viros, et al.
Frontiers in Immunology|April 10, 2024
Induction of islet autoimmunity to defective ribosomal product of the insulin gene as neoantigen after anti-cancer immunotherapy leading to autoimmune diabetesRene van Tienhoven, Diahann T S L Jansen, Miso Park, et al.
European Urology|April 4, 2026
KIM-1 in Advanced Papillary and Clear Cell Renal Cell CarcinomaSara Coca Membribes, Wenxin Xu, Cristina Suárez, et al.
Nature Reviews. Disease Primers|March 10, 2017
Renal cell carcinomaJames J Hsieh, Mark P Purdue, Sabina Signoretti, et al.
The International Journal of Artificial Organs|February 9, 2026
Theoretically redesigning peritoneal dialysis products for sustainability: A life cycle inventory approachJames Larkin, Giulia Ligabue, Gaetano Alfano, et al.
Pageof 42

Showing results (171-180 of 418) with videos related to

Sort By:
Pageof 42
Journal of Nephrology|November 1, 2025
Green haemodialysis: comparison of dialysis bags versus fresenius granumix at the AOU Policlinico di Modena, ItalyJames Larkin, Gaetano Alfano, Giulia Ligabue, et al.
Journal for Immunotherapy of Cancer|June 14, 2020
Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategyJohn Haanen, Marc Ernstoff, Yinghong Wang, et al.
American Journal of Clinical Oncology|January 30, 2013
Axitinib for the treatment of metastatic renal cell carcinoma: recommendations for therapy management to optimize outcomesJames Larkin, Mayer Fishman, Laura Wood, et al.
Expert Opinion on Pharmacotherapy|December 22, 2012
Second-line treatments for the management of advanced renal cell carcinoma: systematic review and meta-analysisJames Larkin, Abby Paine, Indra Tumur, et al.
Cancer Chemotherapy and Pharmacology|November 6, 2013
A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC)Ana M Molina, Thomas E Hutson, James Larkin, et al.
Cancer Cell|April 16, 2015
Intravital imaging reveals how BRAF inhibition generates drug-tolerant microenvironments with high integrin β1/FAK signalingEishu Hirata, Maria Romina Girotti, Amaya Viros, et al.
Frontiers in Immunology|April 10, 2024
Induction of islet autoimmunity to defective ribosomal product of the insulin gene as neoantigen after anti-cancer immunotherapy leading to autoimmune diabetesRene van Tienhoven, Diahann T S L Jansen, Miso Park, et al.
European Urology|April 4, 2026
KIM-1 in Advanced Papillary and Clear Cell Renal Cell CarcinomaSara Coca Membribes, Wenxin Xu, Cristina Suárez, et al.
Nature Reviews. Disease Primers|March 10, 2017
Renal cell carcinomaJames J Hsieh, Mark P Purdue, Sabina Signoretti, et al.
The International Journal of Artificial Organs|February 9, 2026
Theoretically redesigning peritoneal dialysis products for sustainability: A life cycle inventory approachJames Larkin, Giulia Ligabue, Gaetano Alfano, et al.
Pageof 42